NantHealth & NantOmics to Present Patterns of Immune Checkpoint Molecules in Relation to PD-L1 Expression at the American Soc...
June 02 2018 - 4:19PM
Business Wire
Results to be presented during the tumor
biology session at the ASCO 2018 Annual Meeting
NantWorks, LLC today announced that its affiliate companies,
NantHealth, Inc., (NASDAQ: NH), a leading next-generation,
evidence-based, personalized healthcare company and NantOmics, LLC,
the leader in molecular analysis and a member of the NantWorks
ecosystem of companies, will present findings on how targeting
immune checkpoints and employing combinations has led to clinical
benefit across a variety of tumor types during the tumor biology
session at the American Society of Clinical Oncology (ASCO) 2018
Annual Meeting, an event bringing together 30,000 oncology
professionals from June 1-5, 2018 at McCormick Place in Chicago,
Illinois. NantWorks will be exhibiting at booth #7147 during the
event.
“We are excited to share data on how profiling the tumor and
associated microenvironment can help tailor rational combinations
of immunotherapeutic strategies,” said Patrick Soon-Shiong, MD,
founder of NantWorks. “This data is an important step in enhancing
response rates through individualized immune checkpoints in PD-L1
expression, and we look forward to continued exploration and
potential solutions for patients.”
Presentation Details
Co-expression patterns of immune checkpoint molecules in
relation to PD-L1 expression, Abstract #12113WHO:
NantHealth, LLC and NantOmics, LLCWHAT: Tumor Biology
SessionWHEN: June 4, 1:15-4:45 PM CSTWHERE: Hall A,
McCormick Place
Presentation Summary
In order to determine if tailored rational combinations of
immunotherapeutic strategies can be achieved by profiling the tumor
and associated microenvironment, whole transcriptomic sequencing of
1,880 unselected clinical cases, reflecting 38 distinct
histologies, was performed. Cases were categorized as PD-L1-low,
PD-L1-normal and PD-L1-high by cutoffs defined in TCGA expression
profiles. The results found that high and low PD-L1 expression in
the tumor and adjacent microenvironment are associated with
variations in key checkpoint molecules. The results also found that
low expression of PD-L1 may be an ideal setting for use of IDO- or
TIM3-directed therapies.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-based, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth's
unique systems-based approach to personalized healthcare applies
novel diagnostics tailored to the specific molecular profiles of
patient tissue and integrates this molecular data in a clinical
setting with large-scale, real-time biometric signal and phenotypic
data to track patient outcomes and deliver precision medicine. For
nearly a decade, NantHealth has developed an adaptive learning
system that integrates our unique molecular profiling solution,
software and hardware. Our system infrastructure collects, indexes,
analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and
traditional sources to continuously improve decision-making and
optimize our clinical pathways and decision algorithms over time.
For more information please visit www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies,
delivers molecular analysis capabilities with the intent of
providing actionable intelligence and molecularly driven decision
support for cancer patients and their providers at the point of
care. NantOmics is the first molecular analysis company to pioneer
an integrated approach to unearthing the genomic and proteomic
variances that initiate and drive cancer, by analyzing both normal
and tumor cells from the same patient and following identified
variances through from DNA to RNA to protein to drug. NantOmics has
a highly scalable cloud-based infrastructure capable of storing and
processing thousands of genomes a day, computing genomic variances
in near real-time, and correlating proteomic pathway analysis with
quantitative multi-plexed protein expression analysis from the same
micro-dissected tumor sample used for genomic analysis. For more
information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180602005097/en/
NANTJen Hodsonjhodson@nantworks.comorNANTHenry C.
Jacksoncj@nantworks.com
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jun 2024 to Jul 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jul 2023 to Jul 2024